ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Illumina announces expansion of TruSight Oncology portfolio
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology Customer-led research and presentations at...
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...
Illumina, Inc. (ILMN) Q3 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Corporate Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executi...
Here's Why Illumina (ILMN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Revisiting Illumina
Illumina's stock has rebounded 25% since October 2023, despite underwhelming revenue growth and challenges with the NovaSeq X platform and macro headwinds. The company faces issues with the adoptio...
European Court of Justice rules in favor of Illumina in jurisdictional appeal
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment to...
EU top court backs Illumina fight against EU probe into Grail deal
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances...
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)
Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2...
Illumina Looks Bullish (Technical Analysis)
ILMN has shown bullish signs with price action improving, above 30-week EMA, and potential for trend change. Volume analysis indicates institutional buying, momentum is short-term bullish, and long...
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.
Illumina launches new oncology menu for NovaSeq X Series customers
Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers SAN DIEGO , Aug. 5...
Related Companies